BILL ANALYSIS

HR6218

NEUTRAL

HEAR Act of 2025

HR6218 (HEAR Act of 2025) has been assessed with a neutral outlook for investors. This legislation directly affects $ALGN, $BBWI, Boston Scientific ($BSX) and $GNRC and 8 other tickers. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

neutral

Market Sentiment

Affected Stocks

Sectors Impacted

Key Takeaways for Investors

HR6218 has zero legislative momentum: no hearings, no markup, no Senate companion, and no funding mechanism.

None of the provided tickers are pure-play hearing aid manufacturers; the listed medtech majors have negligible hearing aid exposure.

The bill's impact on any publicly traded US equity is currently zero — it is a non-event for market pricing.

Even if passed, implementation would require years of rulemaking and separate appropriation, with no direct revenue impact before 2028 at the earliest.

How HR6218 Affects the Market

No market implications. The HEAR Act of 2025 is an early-stage, unfunded, bipartisan-light bill with no action in over five months. None of the provided tickers have a direct causal link to the bill's mechanism. Investors should ignore this bill for portfolio decisions until and unless it receives a committee hearing and a funded legislative vehicle emerges.

Bill Details

Metric	Value
Bill Number	HR6218
Market Sentiment	neutral
Event Date	November 20, 2025
Affected Sectors	Healthcare
Affected Stocks	$ALGN, $BBWI, Boston Scientific ($BSX), $GNRC, Medtronic ($MDT), $NVMI, $OSUR, $SONO, Stryker ($SYK), $WSB, $WSBC, Zimmer Biomet ($ZBH)
Source	View on Congress.gov →

Summary

The HEAR Act of 2025 is an early-stage, unfunded bill with no Senate companion, no committee hearing, and no markup. It proposes Medicare coverage for hearing aids, which would expand the total addressable market for hearing health, but no publicly traded pure-play hearing aid companies are represented in the provided ticker list. The bill has zero legislative momentum and zero appropriated funding, making it a non-event for current market pricing.

Full AI Market Analysis

The HEAR Act of 2025 (HR6218) was introduced on November 20, 2025, by Rep. Mullin (D-CA) and referred to two committees: Energy and Commerce, and Ways and Means. As of April 30, 2026 — over five months later — it has received no hearings, no markup, and no companion Senate bill. The bill proposes amending Medicare to cover hearing aids and aural rehabilitation services, which would be a major structural shift: currently, Medicare does not cover hearing aids unless provided as part of a bundled post-surgical benefit (e.g., cochlear implant activation). The Congressional Budget Office would need to score this as a new entitlement with significant costs, yet no funding mechanism is included in the bill text. The bill is an authorization-only measure — it sets policy but does not appropriate any dollars. Without a funding stream (e.g., premium increases, federal budget outlays, or offsetting cuts), it cannot become operational. Six cosponsors, all Democrats or independents, suggests limited bipartisan momentum in a divided 119th Congress with a Republican-controlled House. The provided tickers — Sonos ($SONO), Generac ($GNRC), WesBanco ($WSBC), OraSure ($OSUR), Align ($ALGN), Nova ($NVMI), Zimmer Biomet ($ZBH), Stryker ($SYK), Boston Scientific ($BSX), Medtronic ($MDT) — have no material hearing aid exposure. The major hearing aid pure-plays (Sonova, Demant, WS Audiology, GN Hearing) are not US-listed. The medtech majors listed derive negligible revenue from hearing aids; their hearing businesses, if any, are small divisions of diversified device portfolios. Therefore, no actionable causal chain can be constructed. The competitive landscape for hearing aids in the US is dominated by the 'Big Five' private European manufacturers (Sonova, Demant, WS Audiology, GN Hearing, Starkey) and the recent FDA OTC hearing aid rule (2022) has opened the market to $WSB and $BBWI-adjacent consumer electronics entrants, but none of these are supported by the ticker set. Legislative steps remaining: committee markups in both Energy & Commerce and Ways & Means, House floor vote, Senate introduction and passage (no companion exists), conference, and a funded appropriations vehicle. Given zero movement in five months, this bill is effectively stalled and will not affect 2026 earnings for any listed company.